Remdesivir’s Approval for Covid Doesn't Erase Doubts

(Bloomberg Opinion) — Gilead Sciences Inc.’s remdesivir, now under the brand name Veklury, reached another milestone Thursday. It is now the first medicine to get full Food and Drug Administration approval to treat Covid-19. Investors seem to see the nod as a boost to the drug’s prospects, sending shares up more than 4% in early trading Friday after a recent slump. The agency’s decision isn’t likely to dramatically expand the use of the medicine, which has been available to patients through emergency use authorization since May. The data surrounding its modest benefit has become muddier, and it’s not clear why …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.